Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up

Annals of Oncology

Volumn 18, Issue 6, 2007, Pages 1085-1089

  Björkholm, Magnus ^a   Hagberg, H ^b   Holte, H ^c   Kvaloy, S ^c   Teerenhovi, L ^d   Anderson, H ^e   Cavallin Stahl E ^f   Myhre, J ^g   Pertovaara, H ^h   Ost A ^i,j   Nilsson, B ^a   Osby E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e LUND UNIVERSITY   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g FINSEN LABORATORY   (Denmark)

^h TAMPERE UNIVERSITY HOSPITAL   (Finland)

ⁱ Medilab ^*  (Sweden)

^j KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Aggressive non Hodgkin's lymphoma; Central nervous system; CHOP; CNOP; Elderly; G CSF

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; METHOTREXATE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW METASTASIS; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL OBSERVATION; CONTROLLED STUDY; ELDERLY CARE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TESTIS CANCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM STAGING; PREDNISONE; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS; VINCRISTINE;

EID: 34447272204     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm073     Document Type: Article

References (22)

1. Vose JM, Armitage JO, Weisenburger DD et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838-1844.
2. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
3. Osby E, Hagberg H, Kvaloy S et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: Results of a Nordic Lymphoma Group randomized trial. Blood 2003; 101: 3840-3848.
4. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
5. Hollender A, Kvaloy S, Lote K et al. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 2000; 36: 1762-1768.
6. Bashir RM, Bierman PJ, Vose JM et al. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 1991; 14: 478-482.
7. Bos GM, van Putten WL, van der Holt B et al. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol 1998; 9: 191-194.
8. Ersboll J, Schultz HB, Thomsen BL et al. Meningeal involvement in non-Hodgkin's lymphoma: Symptoms, incidence, risk factors and treatment. Scand J Haematol 1985; 35: 487-496.
9. Hollender A, Kvaloy S, Nome O et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: A risk model. Ann Oncol 2002; 13: 1099-1107.
10. van Besien K, Ha CS, Murphy S et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91: 1178-1184.
11. Zinzani PL, Magagnoli M, Frezza G et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: The Bologna experience. Leuk Lymphoma 1999 32: 571-576.
12. Cheung CW, Burton C, Smith P et al. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: Current practice in the UK. Br J Haematol 2005; 131: 193-200.
13. Mazhar D, Stebbing J, Bower M. Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals. Expert Rev Anticancer Ther 2006; 6: 335-341.
14. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
15. Feugier P, Virion JM, Tilly H et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab. Ann Oncol 2004; 15: 129-133.
16. Ohnishi T, Tamai I, Sakanaka K et al. In vivo and in vitro evidence for ATP-dependency of P-glycoprotein mediated efflux of doxorubicin at the blood-brain barrier. Biochem Pharmacol 1995; 49: 1541-1544.
17. Stewart DJ, Green RM, Mikhael NZ et al. Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 1986; 70: 1255-1261.
18. Dietlein M, Pels H, Schulz H et al. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol 2005; 74: 348-352.
19. Boehme V, Seynalova S, Kloess M et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18: 149-157.
20. Tilly H, Lepage E, Coiffier B et al. Intensive, conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-4289.
21. Hegde U, Filie A, Little RF et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: The role of flow cytometry versus cytology. Blood 2005; 105: 496-502.
22. Glantz MJ, LaFollette S, Jaeckle KA et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17: 3110-3116.